First in Human Study of TORL-1-23
Phase 1
90
about 5 years
18+
9 sites in CA, KY, MN +4
What this study is about
Researchers are testing a new medication called TORL-1-23 to see if it's safe and effective for people with advanced cancer. The trial will last about 18 months and involve approximately 90 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take TORL-1-23
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence and severity of adverse events and serious adverse events, Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D)
Secondary: 1 Year Overall Survival (1YOS), 2 Year Overall Survival (2YOS), Clearance (CL) of TORL-1-23, Duration of Response (DOR), Maximum Serum Concentration of TORL-1-23 (Cmax), Maximum Serum Concentration of TORL-1-23 at Steady State (Cmax,ss), Objective Response Rate (ORR), Progression Free Survival (PFS)
Oncology